Looks very promising! It’s great to see some fascinating microfluidics making some sense of the fascinating, often swampy, RNA transcriptome data landscape.
Accurate clinical translation of preclinical research remains challenging, primarily due to species-specific differences and disease and patient heterogeneity. Given this, how do you know how relevant your model is? This study by Javelin Biotech describes the development of pathway-based similarity measurement (PBSM), which leverages RNA-seq data and pathway-based information to assess the human relevance of preclinical models for specific CoU. This figure shows PBSM-based scores for pre-clinical animal models of nonalcoholic fatty liver disease compared to reference human NAFL liver tissue samples for the KEGG NAFL pathway. There is a room for improvement - Stay tuned for more about Javelin’s human healthy and disease models! bioRxiv preprint: https://lnkd.in/dUZVAGCD
